MCID: MXD026
MIFTS: 45

Mixed Glioma

Categories: Bone diseases, Cancer diseases, Neuronal diseases

Aliases & Classifications for Mixed Glioma

MalaCards integrated aliases for Mixed Glioma:

Name: Mixed Glioma 12 54 15
Mixed Gliomas 12 71
Mixed Neuroglial Tumor 12
Glioma 71

Classifications:



External Ids:

Disease Ontology 12 DOID:5076
MeSH 43 D005910
NCIt 49 C3903
SNOMED-CT 67 22217002 443937008
UMLS 71 C0017638 C0259783

Summaries for Mixed Glioma

MalaCards based summary : Mixed Glioma, also known as mixed gliomas, is related to oligoastrocytoma and mixed oligodendroglioma-astrocytoma. An important gene associated with Mixed Glioma is GFAP (Glial Fibrillary Acidic Protein), and among its related pathways/superpathways are Glioma and MicroRNAs in cancer. The drugs Midazolam and Dexmedetomidine have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and testes, and related phenotypes are Decreased sensitivity to paclitaxel and growth/size/body region

Related Diseases for Mixed Glioma

Diseases related to Mixed Glioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 213)
# Related Disease Score Top Affiliating Genes
1 oligoastrocytoma 33.0 MGMT IDH2 GFAP
2 mixed oligodendroglioma-astrocytoma 31.9 TP53 PTEN MGMT IDH2 IDH1 ATRX
3 glial tumor 30.8 PTEN OLIG2 IDH1
4 anaplastic oligodendroglioma 30.3 OLIG2 MGMT IDH2
5 neuroma 29.8 NF1 MGMT GFAP
6 glioma 29.3 TP53 PTEN PDGFRA NF1 IDH2 IDH1
7 rhabdomyosarcoma 28.8 TP53 PTEN PDGFRA NES EGFR
8 malignant glioma 28.7 TP53 PTEN MGMT GFAP EGFR CCDC26
9 benign ependymoma 28.6 PDGFRA NF1 NES MGMT GFAP EGFR
10 gliomatosis cerebri 28.6 TP53 PTEN NES IDH1 GFAP EGFR
11 juvenile pilocytic astrocytoma 28.1 PTEN OLIG2 NF1 NES MGMT IDH1
12 oligodendroglioma 27.5 TP53 PTEN PDGFRA OLIG2 NF1 MGMT
13 glioma susceptibility 1 27.5 TP53 PTEN PDGFRA OLIG2 NES MGMT
14 glioblastoma multiforme 27.1 TP53 PTEN PDGFRA NF1 NES MGMT
15 adult brainstem mixed glioma 12.4
16 anaplastic oligoastrocytoma 11.7
17 extraventricular neurocytoma 10.5 IDH1 GFAP
18 enchondroma 10.5 IDH2 IDH1
19 deep leiomyoma 10.5 PDGFRA GFAP
20 breast intraductal papillomatosis 10.5 IDH2 IDH1
21 third ventricle chordoid glioma 10.5 OLIG2 GFAP
22 breast papillomatosis 10.5 IDH2 IDH1
23 cytogenetically normal acute myeloid leukemia 10.5 IDH2 IDH1
24 angiocentric glioma 10.5 IDH1 GFAP
25 intracranial chondrosarcoma 10.5 IDH2 IDH1
26 tanycytic ependymoma 10.5 OLIG2 GFAP
27 spinal cord astrocytoma 10.4 MGMT IDH1
28 periosteal chondrosarcoma 10.4 IDH2 IDH1
29 urethra transitional cell carcinoma 10.4 TP53 GFAP
30 laryngeal neuroendocrine tumor 10.4 TP53 IDH1
31 juxtacortical chondroma 10.4 IDH2 IDH1
32 esophageal basaloid squamous cell carcinoma 10.4 TP53 EGFR
33 esophagus verrucous carcinoma 10.4 TP53 EGFR
34 clear cell ependymoma 10.4 OLIG2 IDH1 GFAP
35 interval angle-closure glaucoma 10.4 IDH2 IDH1
36 supratentorial primitive neuroectodermal tumor 10.4 OLIG2 IDH1 GFAP
37 adult brain stem glioma 10.3 MGMT IDH2 IDH1
38 protoplasmic astrocytoma 10.3 PHLDB1 IDH2
39 cervical adenosquamous carcinoma 10.3 PDGFRA EGFR
40 soft tissue sarcoma 10.3 TP53 EGFR
41 systemic mastocytosis 10.3 PDGFRA IDH2 IDH1
42 breast hemangioma 10.3 TP53 IDH2 IDH1
43 chondroblastic osteosarcoma 10.3 TP53 IDH2 IDH1
44 breast malignant phyllodes tumor 10.3 TP53 EGFR
45 cerebrovascular benign neoplasm 10.3 TP53 GFAP
46 choroid plexus cancer 10.3 TP53 GFAP ATRX
47 high-grade astrocytoma 10.3 PTEN IDH1
48 atypical teratoid rhabdoid tumor 10.3 TP53 GFAP ATRX
49 anaplastic ganglioglioma 10.2 NES GFAP
50 small intestine leiomyoma 10.2 PDGFRA NF1

Graphical network of the top 20 diseases related to Mixed Glioma:



Diseases related to Mixed Glioma

Symptoms & Phenotypes for Mixed Glioma

GenomeRNAi Phenotypes related to Mixed Glioma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased sensitivity to paclitaxel GR00112-A-0 8.62 NF1 PTEN

MGI Mouse Phenotypes related to Mixed Glioma:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.26 ATRX EGFR FUBP1 GFAP IDH1 NF1
2 cardiovascular system MP:0005385 10.21 ATRX EGFR FUBP1 GFAP IDH2 NF1
3 mortality/aging MP:0010768 10.21 ATRX EGFR FUBP1 GFAP IDH1 MGMT
4 embryo MP:0005380 10.1 ATRX EGFR FUBP1 NF1 PDGFRA PTEN
5 nervous system MP:0003631 10.02 ATRX EGFR FUBP1 GFAP MGMT NF1
6 muscle MP:0005369 10.01 EGFR GFAP NF1 OLIG2 PDGFRA PTEN
7 neoplasm MP:0002006 9.97 EGFR IDH2 MGMT NF1 OLIG2 PDGFRA
8 limbs/digits/tail MP:0005371 9.93 EGFR IDH2 NF1 PDGFRA PTEN TP53
9 respiratory system MP:0005388 9.81 EGFR FUBP1 IDH1 MGMT NF1 OLIG2
10 pigmentation MP:0001186 9.65 EGFR NF1 PDGFRA PTEN TP53
11 skeleton MP:0005390 9.65 EGFR IDH1 IDH2 NF1 OLIG2 PDGFRA
12 vision/eye MP:0005391 9.23 ATRX EGFR FUBP1 GFAP NF1 OLIG2

Drugs & Therapeutics for Mixed Glioma

Drugs for Mixed Glioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 556)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
2
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
3
Glutamic acid Approved, Nutraceutical Phase 4 56-86-0 33032
4 Anti-Anxiety Agents Phase 4
5 Excitatory Amino Acid Antagonists Phase 4
6 alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid Phase 4
7 Analgesics, Non-Narcotic Phase 4
8 Analgesics Phase 4
9 Anesthetics Phase 4
10 Hypnotics and Sedatives Phase 4
11 Adrenergic Agents Phase 4
12 Adrenergic alpha-Agonists Phase 4
13 Adrenergic Agonists Phase 4
14
Lenograstim Approved, Investigational Phase 3 135968-09-1
15
Thiotepa Approved, Investigational Phase 3 52-24-4 5453
16
Dextroamphetamine Approved, Illicit Phase 3 51-64-9 5826
17
Donepezil Approved Phase 3 120014-06-4 3152
18
Heparin Approved, Investigational Phase 3 9005-49-6 46507594 772
19
Dalteparin Approved Phase 3 9005-49-6
20
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
21
Somatostatin Approved, Investigational Phase 2, Phase 3 38916-34-6, 51110-01-1 53481605
22
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
23
Thioguanine Approved Phase 3 154-42-7 2723601
24
chloroquine Approved, Investigational, Vet_approved Phase 3 54-05-7 2719
25
Ethanol Approved Phase 2, Phase 3 64-17-5 702
26
Disulfiram Approved Phase 2, Phase 3 97-77-8 3117
27
Copper Approved, Investigational Phase 2, Phase 3 7440-50-8 27099
28
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
29
Irinotecan Approved, Investigational Phase 3 97682-44-5, 100286-90-6 60838
30
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
31
Etoposide Approved Phase 3 33419-42-0 36462
32
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
33
leucovorin Approved Phase 3 58-05-9 6006 143
34
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
35
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
36
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
37
Histamine Approved, Investigational Phase 3 51-45-6 774
38
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
39
Cyproheptadine Approved Phase 3 129-03-3 2913
40
Norepinephrine Approved Phase 3 51-41-2 439260
41
Dactinomycin Approved, Investigational Phase 3 50-76-0 457193 2019
42
Vitamin C Approved, Nutraceutical Phase 3 50-81-7 5785 54670067
43
Ornithine Approved, Nutraceutical Phase 3 70-26-8, 3184-13-2 6262
44
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
45 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
46 Dianhydrogalactitol Investigational Phase 3 23261-20-3
47 Emetics Phase 3
48 Hematoporphyrins Phase 3
49 Anesthetics, Inhalation Phase 3
50 Cholinesterase Inhibitors Phase 3

Interventional clinical trials:

(show top 50) (show all 1444)
# Name Status NCT ID Phase Drugs
1 A Prospective, Single-Blinded, Randomized Study of Awake vs Intubated General Anesthesia in Patients Undergoing Elective Craniotomy for Supratentorial Glioma Resection Completed NCT02193568 Phase 4
2 Phase II Feasibility Study to Evaluate the Efficacy and Safety of Perampanel in Seizure Patients With Primary Glial Brain Tumors Completed NCT02363933 Phase 4 Perampanel
3 Seizure Treatment IN Glioma (STING): Comparing a Treatment Strategy With Levetiracetam Versus Treatment With Valproic Acid in Glioma Patients With a First Seizure Recruiting NCT03048084 Phase 4 Levetiracetam;Valproic Acid
4 An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) Recruiting NCT03975829 Phase 4 dabrafenib;trametinib
5 Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study Recruiting NCT03340506 Phase 4 dabrafenib;trametinib
6 Effect of Dexmedetomidine on Brain Homeostasis and Neurocognitive Outcome of Patients Undergoing Brain Tumor Exclusion Recruiting NCT04266665 Phase 4 Dexmedetomidine
7 A Study of CIK in Combination With Temozolomide With and Without Radiation in Adults With Advanced Malignant Gliomas Not yet recruiting NCT02496988 Phase 4 Temozolomide
8 Cognitive Rehabilitation of Glioma Patients: a Prospective, Randomized Study Unknown status NCT00256425 Phase 3
9 A Phase III Trial on Adjuvant Standard Temozolomide Chemotherapy With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas Unknown status NCT01765088 Phase 3 Temozolomide;α-IFN
10 Randomized Controlled Multicenter Trial on the Impact of Presurgical Navigated Transcranial Magnetic Stimulation for Motor Mapping of Rolandic Lesions Unknown status NCT02879682 Phase 3
11 Prospective Randomized Trial of Two Hypofractionated Radiotherapy Regimens Versus Conventional Radiotherapy in Pediatric Diffuse Brainstem Glioma Unknown status NCT01878266 Phase 3
12 Phase 3 Study of Carmustine Sustained Release Implant (CASANT) to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
13 Impact of Surgery on the Treatment of Supratentorial Malignant Gliomas in Subjects Aged 70 and Over Unknown status NCT02892708 Phase 3
14 A Study Evaluating Dexamfetamine Sulphate in Patients With Glioma Suffering From Severe Asthenia. A Phase III Double-blind Randomized Placebo-controlled Trial Unknown status NCT02363075 Phase 3 Dexamfetamine sulphate;placebo
15 Ultimate Low Grade Glioma Study Unknown status NCT00003015 Phase 3 carboplatin;vincristine sulfate
16 Barrow 5-ALA Intraoperative Confocal Evaluation Trial Unknown status NCT01502280 Phase 3 5-Aminolevulinic acid (ALA);Placebo - ascorbic acid
17 A Prospective, Randomized, Controlled, Double-blind, Multi-center Clinical Study of Nimotuzumab Combinated With Gemcitabine Contrast to Placebo Combinated With Gemcitabine in K-RAS Wild-type,Locally Advanced and Metastatic Pancreatic Cancer Unknown status NCT02395016 Phase 3 nimotuzumab;Gemcitabine
18 Treatment of Children and Adolescents With Diffuse Intrinsic Pontine Glioma and High Grade Glioma Unknown status NCT00278278 Phase 3 cisplatin;etoposide;ifosfamide;lomustine;methotrexate;prednisone;vincristine sulfate
19 A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM) Unknown status NCT00045968 Phase 3 Dendritic cell immunotherapy
20 A Prospective,Randomized,Double-Blind,Controlled,Multicenter,Phase III Study of Nimotuzumab in Combination With Chemotherapy and Radiotherapy for Patients With Local Advanced Nasopharyngeal Cancer Unknown status NCT01074021 Phase 3 Nimotuzumab;placebo plus chemoradiotherapy
21 Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III] Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
22 A Phase III Randomized Study (Phase I Closed) of Radiation Therapy and Temozolomide Versus Radiation Therapy and Nitrosourea for Anaplastic Astrocytoma And Mixed Anaplastic Oligoastrocytoma (Astrocytoma Dominant) Completed NCT00004259 Phase 3 BCNU 80mg/m2;TMZ 200mg/m2;CCNU;BCNU 150mg/m2;BCNU 200mg/m2;TMZ 150mg/m2 six 6-week cycles;TMZ 150mg/m2 six 8-week cycles
23 A Randomized Prospective Two Arm Clinical Trial of High Light Dose And Low Light Dose PDT in the Treatment of Recurrent Malignant Supratentorial Gliomas Using Porfimer Sodium [Photofrin] Completed NCT00118222 Phase 3 porfimer sodium
24 Phase III Double Blind, Placebo Controlled Study of Donepezil in the Irradiated Brain Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
25 Primary Chemotherapy With Temozolomide Versus Radiotherapy in Patients With Low Grade Gliomas After Stratification for Genetic 1p Loss: A Phase III Study Completed NCT00182819 Phase 3 temozolomide
26 Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
27 PHASE III STUDY OF ADJUVANT PROCARBAZINE, CCNU AND VINCRISTINE CHEMOTHERAPY IN PATIENTS WITH HIGHLY ANAPLASTIC OLIGODENDROGLIOMA Completed NCT00002840 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
28 Phase III Intergroup Randomized Comparison of Radiation Alone vs. Pre-Radiation Chemotherapy for Pure and Mixed Anaplastic Oligodendrogliomas Completed NCT00002569 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
29 A Phase III Comparison of Hyperfractionated Radiation Therapy (RT) With BCNU and Conventional RT With BCNU for Supratentorial Malignant Glioma Completed NCT03722355 Phase 3 Carmustine
30 PET/CT Imaging of Malignant Glioma With Somatostatin Analog 68Ga-DOTATOC Completed NCT01460706 Phase 2, Phase 3 [68Ga]DOTATOC
31 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
32 A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma Completed NCT01781468 Phase 3 armodafinil 150 mg;armodafinil 250 mg
33 A Trial of Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients (PRODIGE) Completed NCT00135876 Phase 3 dalteparin
34 Clinical Study to Assess the Positive Predictive Value of NPC-07 Induced Tissue Fluorescence in Patients With Malignant Glioma (WHO Grades III/IV) Completed NCT01167322 Phase 3 NPC-07 for oral administration
35 Prospective Randomized Trial of Hypofractionated Radiotherapy Versus Conventional Radiotherapy in Diffuse Brainstem Glioma in Children. Completed NCT01635140 Phase 3
36 A Phase II Study of Observation in Favorable Low-Grade Glioma and a Phase II Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade Glioma Completed NCT00003375 Phase 2, Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
37 Focal Fractionated Conformal Stereotactic Boost Following Conventional Radiotherapy of High Grade Gliomas: A Randomized Phase III Study Completed NCT00003916 Phase 3
38 A Prospective Randomised Trial Comparing Temozolomide With PCV In The Treatment Of Recurrent WHO Astrocytic Tumours Grades III And IV Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
39 Chemotherapy for Progressive Low Grade Astrocytoma in Children Less Than Ten Years Old Completed NCT00002944 Phase 3 carboplatin;lomustine;procarbazine hydrochloride;thioguanine;vincristine sulfate
40 A Phase III Randomized Trial for the Treatment of Pediatric High Grade Gliomas at First Recurrence With a Single High Dose Chemotherapy and Autologous Stem Cell Transplant Versus Three Courses of Intermediate Dose Chemotherapy With Peripheral Blood Stem Cell (PBSC) Support Completed NCT00078988 Phase 3 carboplatin;etoposide;isotretinoin;thiotepa
41 Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid (5-ALA) vs. Conventional Resection Completed NCT00241670 Phase 3 5-aminolevulinic acid (5-ALA)
42 Randomized Study of Normal-fractionated Radiotherapy Versus Hypofractionated Radiotherapy Versus Chemotherapy in Patients Over 60 Years With Malignant Glioma Completed NCT00820963 Phase 3 temozolomide
43 NOA-04 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3 Temozolomide
44 Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT00884741 Phase 3 Temozolomide
45 PRECISE - Phase III Randomized Evaluation of Convection Enhanced Delivery of IL13-PE38QQR Compared to GLIADEL® Wafer With Survival Endpoint in Glioblastoma Multiforme Patients at First Recurrence Completed NCT00076986 Phase 3 IL13-PE38QQR;prolifespan 20 with carmustine implant (GLIADEL® Wafer)
46 A RANDOMIZED, MULTICENTER, PHASE IIB/IIIA STUDY OF GEMCITABINE AND THE MONOCLONAL ANTIBODY NIMOTUZUMAB (OSAG 101) VERSUS GEMCITABINE AND PLACEBO FOR THE TREATMENT OF CHEMOTHERAPY-NAIVE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER Completed NCT00561990 Phase 2, Phase 3 Nimotuzumab
47 Chloroquine as Adjuvant to the Treatment of Glioblastoma Multiforme, A Randomized Trial Completed NCT00224978 Phase 3 Chloroquine
48 Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma Recruiting NCT00887146 Phase 3 concomitant temozolomide (TMZ);procarbazine;adjuvant temozolomide (TMZ);CCNU;vincristine
49 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation Recruiting NCT04164901 Phase 3 AG-881;Matching Placebo
50 A Study on β-elemene as Maintain Treatment for Complete Remission Patients of Newly Diagnosed Malignant Gliomas Following Standard Treatment Recruiting NCT02629757 Phase 3 β-elemene

Search NIH Clinical Center for Mixed Glioma

Genetic Tests for Mixed Glioma

Anatomical Context for Mixed Glioma

MalaCards organs/tissues related to Mixed Glioma:

40
Brain, T Cells, Testes, Breast, Spinal Cord, Bone, Endothelial

Publications for Mixed Glioma

Articles related to Mixed Glioma:

(show top 50) (show all 301)
# Title Authors PMID Year
1
A PDGFRA promoter polymorphism, which disrupts the binding of ZNF148, is associated with primitive neuroectodermal tumours and ependymomas. 61 54
15635072 2005
2
Tissue culture of human neurocytomas induces the expression of glial fibrilary acidic protein. 54 61
10451427 1998
3
Semiquantitative postembedding characterization of intermediate filaments in central nervous system lesions using immunoelectron microscopy. 54 61
9044656 1995
4
Sex is an important prognostic factor for glioblastoma but not for nonglioblastoma. 61
31832215 2019
5
Synchronous identification of a dysembryoplastic neuroepithelial tumor (DNET) and an oligodendroglioma in a patient: A case report. 61
31262396 2019
6
Diagnosing growth in low-grade gliomas with and without longitudinal volume measurements: A retrospective observational study. 61
31136584 2019
7
Concurrent Versus Sequential Chemoradiation for Low-grade Gliomas Meeting RTOG 9802 Criteria. 61
30768441 2019
8
Glioblastoma in the setting of prior lower grade gliomas - insights from SEER database. 61
30279958 2018
9
Reclassification of Mixed Oligoastrocytic Tumors Using a Genetically Integrated Diagnostic Approach. 61
28958143 2018
10
[Adult intramedullary gliomas]. 61
28527519 2017
11
Malignant transformation of low-grade gliomas in patients undergoing adjuvant therapy. 61
27271289 2017
12
Clinicopathological features and microsurgical outcomes for giant pediatric intracranial tumor in 60 consecutive cases. 61
28180935 2017
13
The inhibiting activity of meadowsweet extract on neurocarcinogenesis induced transplacentally in rats by ethylnitrosourea. 61
27838807 2017
14
Proceedings of the 2016 National Toxicology Program Satellite Symposium. 61
27821709 2017
15
Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With IDH-Mutant Glioma. 61
28248126 2016
16
Unique case of oligoastrocytoma with recurrence and grade progression: Exhibiting differential expression of high mobility group-A1 and human telomerase reverse transcriptase. 61
27672647 2016
17
Morphological Patterns of Intracranial Lesions in a Tertiary Care Hospital in North Karnataka: A Clinicopathological and Immunohistochemical Study. 61
27656442 2016
18
Nogo-A inhibits the migration and invasion of human malignant glioma U87MG cells. 61
27109183 2016
19
Primary Spinal Oligoastrocytoma. 61
27092919 2016
20
Analysis of IDH1-R132 mutation, BRAF V600 mutation and KIAA1549-BRAF fusion transcript status in central nervous system tumors supports pediatric tumor classification. 61
26115961 2016
21
The role of imaging in the management of adults with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline. 61
26530262 2015
22
Updates in Molecular Pathology of Central Nervous System Gliomas in Adults. 61
26517249 2015
23
Mixed glioma with molecular features of composite oligodendroglioma and astrocytoma: a true "oligoastrocytoma"? 61
25359109 2015
24
Treatment of anaplastic glioma. 61
25468227 2015
25
[Low-grade gliomas in adults]. 61
25391745 2014
26
Mixed Glioma (Oligoastrocytoma) in the brain of an African Hedgehog (Atelerix albiventris). 61
25172052 2014
27
Polysomy of chromosomes 1 and 19: an underestimated prognostic factor in oligodendroglial tumors. 61
25007776 2014
28
Immunohistochemical evaluation of tissue factor, fibrin/fibrinogen and D-dimers in canine gliomas. 61
24745770 2014
29
Glioma tumor grade correlates with parkin depletion in mutant p53-linked tumors and results from loss of function of p53 transcriptional activity. 61
23644658 2014
30
Trends in childhood brain tumor incidence, 1973-2009. 61
23925828 2013
31
Analyzing agreement patterns of intraoperative central nervous system lesion reporting according to type and grade. 61
24130410 2013
32
The Evangelismos hospital central nervous system tumor registry: Analysis of 1414 cases (1998-2009). 61
23533006 2013
33
GFAP-positive neoplastic astrocytes in spontaneous oligodendrogliomas and mixed gliomas of rats. 61
23076037 2013
34
Immunohistochemical characterization of spontaneous and acrylonitrile-induced brain tumors in the rat. 61
22821367 2013
35
Molecular genetics of adult grade II gliomas: towards a comprehensive tumor classification system. 61
22890969 2012
36
Clonal analysis in recurrent astrocytic, oligoastrocytic and oligodendroglial tumors implicates IDH1- mutation as common tumor initiating event. 61
22844452 2012
37
Histomolecular classification of adult diffuse gliomas: the diagnostic value of immunohistochemical markers. 61
21889777 2011
38
The effect of WHO reclassification of necrotic anaplastic oligoastrocytomas on incidence and survival in glioblastoma. 61
21229290 2011
39
Glioma Indian scenario: Is there a human leucocyte antigen association? 61
22346237 2011
40
Pleomorphic xanthoastrocytoma and oligodendroglioma: collision of 2 morphologically and genetically distinct anaplastic components. 61
21214337 2011
41
Risk factors for oligodendroglial tumors: a pooled international study. 61
21149253 2011
42
Primary and metastatic intraaxial brain tumors: prospective comparison of multivoxel 2D chemical-shift imaging (CSI) proton MR spectroscopy, perfusion MRI, and histopathological findings in a group of 159 patients. 61
21165751 2011
43
[Beneficial outcomes of an interdisciplinary psychoeducative group intervention for patients with malignant gliomas and their relatives]. 61
21312092 2011
44
Coexistent pathology in chronic epilepsy patients with neoplasms. 61
20495542 2010
45
Persistent outpatient hyperglycemia is independently associated with survival, recurrence and malignant degeneration following surgery for hemispheric low grade gliomas. 61
19589201 2010
46
Clinical features, management and outcomes of high-grade glioma patients in Ramathibodi Hospital. 61
21299082 2010
47
Tumours arising in the setting of paediatric chronic epilepsy. 61
20632818 2010
48
Central nervous system. 61
22112477 2010
49
A retrospective study of primary brain tumors in children under 14 years of age at PIMS, Islamabad. 61
21198267 2010
50
Recurrence and malignant degeneration after resection of adult hemispheric low-grade gliomas. 61
19361270 2010

Variations for Mixed Glioma

Expression for Mixed Glioma

Search GEO for disease gene expression data for Mixed Glioma.

Pathways for Mixed Glioma

GO Terms for Mixed Glioma

Cellular components related to Mixed Glioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 PML body GO:0016605 8.8 TP53 PTEN ATRX

Biological processes related to Mixed Glioma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 wound healing GO:0042060 9.61 PDGFRA NF1 EGFR
2 DNA damage response, signal transduction by p53 class mediator GO:0030330 9.49 TP53 ATRX
3 2-oxoglutarate metabolic process GO:0006103 9.48 IDH2 IDH1
4 regulation of synaptic transmission, GABAergic GO:0032228 9.46 PTEN NF1
5 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.4 TP53 EGFR
6 forebrain morphogenesis GO:0048853 9.37 PTEN NF1
7 NADP metabolic process GO:0006739 9.32 IDH2 IDH1
8 negative regulation of neuroblast proliferation GO:0007406 9.26 TP53 NF1
9 response to organic cyclic compound GO:0014070 9.26 PTEN MGMT IDH1 EGFR
10 isocitrate metabolic process GO:0006102 9.16 IDH2 IDH1
11 glyoxylate cycle GO:0006097 8.62 IDH2 IDH1

Molecular functions related to Mixed Glioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 platelet-derived growth factor receptor binding GO:0005161 9.16 PTEN PDGFRA
2 isocitrate dehydrogenase (NADP+) activity GO:0004450 8.96 IDH2 IDH1
3 isocitrate dehydrogenase activity GO:0004448 8.62 IDH2 IDH1

Sources for Mixed Glioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....